Global Blood Therapeutics, Inc. (GBT) News
Filter GBT News Items
GBT News Results
|Loading, please wait...|
GBT News Highlights
- For GBT, its 30 day story count is now at 3.
- Over the past 8 days, the trend for GBT's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about GBT are ACT and MON.
Latest GBT News From Around the Web
Below are the latest news stories about GLOBAL BLOOD THERAPEUTICS INC that investors may wish to consider to help them evaluate GBT as an investment opportunity.
GBT Supports the Sickle Cell Disease Treatment Centers Act of 2022
Congress Moves to Expand Funding for National Network of Specialized Treatment Centers and Community Organizations for Sickle Cell Disease PatientsSOUTH SAN FRANCISCO, Calif., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) announced its support for the Sickle Cell Disease Treatment Centers Act of 2022, which was introduced today and, if passed in its current form, would authorize for appropriations of $535 million in annual funding to support sickle cell d
GBT and Sickle Cell Disease Association of America to Host 11th Annual Sickle Cell Disease Therapeutics Conference
Keynote by Admiral Rachel Levine, M.D., Assistant Secretary for Health, U.S. Department of Health and Human ServicesSOUTH SAN FRANCISCO, Calif. and BALTIMORE, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) and the Sickle Cell Disease Association of America, Inc. (SCDAA) will host the 11th Annual Sickle Cell Disease (SCD) Therapeutics Conference on Wednesday, September 14th. The virtual conference, which takes place during National Sickle Cell Awareness Mon
Global Blood (GBT) Up 1.9% Since Last Earnings Report: Can It Continue?
Global Blood (GBT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
These 10 Non-Covid Biotech Stocks Are Up 40% Or More This Year
Biotech stocks are scorching right now. But the best of the best have strong gains. Those include 10 with at least 40% growth this year.
Pharma Stock Roundup: PFE to Buy GBT, JNJ to Stall Baby Talc Sale Globally From 2023
Pfizer (PFE) offers to buy Global Blood Therapeutics (GBT) for $5.4 billion in cash. J&J (JNJ) to discontinue selling talc-based baby powder globally from 2023.
Get ready for more merger mania in the pharma sector for the rest of the year
Pfizer’s $5.4 billion acquisition of Global Blood Therapeutics is the latest sign that cash-flush drug makers are ready to make some deals.
As Covid Vaccine Boom Ends, Pfizer and Moderna Pursue Opposite Strategies
Pfizer is pursuing M&A with its profits from selling Covid-19 vaccines. Rival Moderna is developing its own pipeline of drugs.
Global Blood (GBT) to be Acquired by Pfizer, Misses on Earnings
Global Blood (GBT) is set to be acquired by Pfizer for around $5.4 billion. The company missed estimates for earnings while beating the same for revenues in the second quarter of 2022.
Analysts Are Neutral on Top Healthcare Stocks: Global Blood Therapeutics (GBT), Cerevel Therapeutics Holdings (CERE)
Analysts fell to the sidelines weighing in on Global Blood Therapeutics (GBT – Research Report) and Cerevel Therapeutics Holdings (CERE – Research Report) with neutral ratings, indicating that the experts are neither bullish nor bearish on the stocks. Global Blood Therapeutics (GBT) In a report released today, Andreas Argyrides from Wedbush downgraded Global Blood Therapeutics to Hold, with a price target of $68.50. The company's shares closed last Monday at $66.67, close to its 52-week high of $73.02. According to TipRanks.
GBT Stock Alert: Pfizer Is Officially Acquiring Global Blood Therapeutics
GBT stock is already rallying on takeover talk.